Skip to main content

Hormone Replacement Therapy and Breast Cancer

  • Chapter
  • First Online:
Clinical Cancer Prevention

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 188))

Abstract

There is evidence that hormone replacement therapy (HRT) may both stimulate and inhibit breast cancers, giving rise to a spectrum of activities, which are frequently hard to understand. Here we summarise the evidence for these paradoxical effects and, given the current data, attempt to give an indication where it may or may not be appropriate to prescribe HRT.

It is clear that administration of oestrogen-progestin (E-P) and oestrogen alone (E) HRT is sufficient to stimulate the growth of overt breast tumours in women since withdrawal of HRT results in reduction of proliferation of primary tumours and withdrawal responses in metastatic tumours. E-P, E including tibolone are associated with increased local and distant relapse when given after surgery for breast cancer. For women given HRT who do not have breast cancer the only large randomised trial (WHI) of E-P or E versus placebo has produced some expected and also paradoxical results. E-P increases breast cancer risk as previously shown in observational studies. Risk is increased, particularly in women known to be compliant. Conversely, E either has no effect or reduces breast cancer risk consistent with some but not all observational studies. Two observational studies report a decrease or at least no increase in risk when E-P or E are given after oophorectomy in young women with BRCA1/2 mutations. Early oophorectomy increases death rates from cardiovascular and other conditions and there is evidence that this may be reversed by the use of E post-oophorectomy. HRT may thus reduce the risk of breast cancer and other diseases (e.g., cardiovascular) in young women and increase or decrease them in older women.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Similar content being viewed by others

References

  • Allen E, Doisy EA (1923) An ovarian hormone. Preliminary report on its localization, extraction and partial purification and action in test animals. JAMA 81:819–821

    Article  CAS  Google Scholar 

  • Anderson GL, Chlebowski RT, Rossouw JE et al (2006) Prior hormone therapy and breast cancer risk in the Women’s Health Initiative randomized trail of estrogen plus progestin. Maturitas 55: 103–15

    Google Scholar 

  • Asselin-Labat ML, Vaillant F, Sheridan JM, et al (2010) Asselin-LabatControl of mammary stem cell function by steroid hormone signalling. Nature. 2010 Apr 11. [Epub ahead of print]

    Google Scholar 

  • Beral V, Million Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 352:419–427

    Google Scholar 

  • Bergkvist L, Adami HO, Persson I et al (1989) The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293–97

    Article  PubMed  CAS  Google Scholar 

  • Bernstein LM, Wang P, Zheng H et al (2004) Long term exposure to tamoxifen induces sensitivity to estrdiol. Clin Cancer Res 10:1530–1534

    Article  Google Scholar 

  • Canfell K, Banks E, Moa AM et al (2008) Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 188:641–644

    PubMed  Google Scholar 

  • Chen WY, Manum JE, Hankinson S et al (2006) Unopposed estrogen therapy and risk of invasive breast cancer. Arch In Med 166:1027–1032

    CAS  Google Scholar 

  • Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trail. JAMA 289: 3243–53

    Google Scholar 

  • Col NF, Kim JA, Chlebowski RT (2005) Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7:R535–R540

    Article  PubMed  CAS  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52, 705 women with breast cancer and 108, 411 women without breast cancer. Lancet 350:1047–1059

    Article  Google Scholar 

  • Cummings SR, Ettinger B, Delmas P et al (2008) The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708

    Article  PubMed  CAS  Google Scholar 

  • Dhodapkar MV, Ingle JN, Ahmann DL (1995) Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75:43–46

    Article  PubMed  CAS  Google Scholar 

  • Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229

    Article  PubMed  CAS  Google Scholar 

  • Dubey RK, Imthurn B, Barton M et al (2005) Vascular consequences of menopause and hormone therapy: importance of timing of treatment and type of estrogen. Cardiovasc Res 66:295–306

    Article  PubMed  CAS  Google Scholar 

  • Eisen A, Lubinski J, Gronwald J et al (2008) Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100:1361–1367

    Article  PubMed  CAS  Google Scholar 

  • Ewertz M, Mellemkjaer L, Poulen AH et al (2005) Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 92:1293–1297

    Article  PubMed  CAS  Google Scholar 

  • Holmberg L, Iversen OE, Rudenstam CM et al (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100:475–482

    Article  PubMed  CAS  Google Scholar 

  • Hoover R, Gray LA Sr, Cole P et al (1976) Menopausal estrogens and breast cancer. N Engl J Med 295:401–405

    Article  PubMed  CAS  Google Scholar 

  • Howell A, Dodwell D, Anderson H et al (1992) Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 3:611–617

    PubMed  CAS  Google Scholar 

  • Kenemans P, Bundred NJ, Foidart JM et al (2009) Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised non-inferiority trial. Lancet Oncol 10:135–146

    Article  PubMed  CAS  Google Scholar 

  • Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28: 222–231

    Article  PubMed  CAS  Google Scholar 

  • Lewis JS, Keeke K, Osipo C et al (2005) Intrinsic mechanism of estrdiol’induced osteoporosis in breast cancer cells resistant to estrogen deprivation. JNCI 97:1746–1759

    Article  PubMed  CAS  Google Scholar 

  • Liu H, Lee ES, Gadjos C et al (2003) Apoptotic action of 17 beta-estradiol in raloxifene resistant MCF-7 cells in-vitro and in-vivo. JNCI 95:1586–1596

    Article  PubMed  CAS  Google Scholar 

  • Lobo RA (2007) Surgical menopause and cardiovascular risks. Menopause 14:562–6

    Article  PubMed  Google Scholar 

  • Madalinska JB, van Beurden M, Bleiker EM et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24:3576–3582

    Article  PubMed  Google Scholar 

  • Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N (2000) Are randomizedtrials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 73:292–299

    Article  PubMed  CAS  Google Scholar 

  • Marshall SF, Clarke CA, Deapen D et al (2010) Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 12:R4

    Article  PubMed  Google Scholar 

  • Parker WH, Broder MS, Chang E et al (2009) Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses health study. Obstet Gynecol 113:1027–1037

    PubMed  Google Scholar 

  • Prasad R, Boland GP, Cramer A et al (2003) Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast cancer. Cancer 98:2539–2546

    Article  PubMed  CAS  Google Scholar 

  • Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674

    Article  PubMed  CAS  Google Scholar 

  • Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810

    Article  PubMed  CAS  Google Scholar 

  • Rivera CM, Grossardt BR, Rhodes DJ et al (2009) Increased cardiovascular mortality after bilateral oophorectomy. Menopause 16:15–23

    Article  PubMed  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiativerandomised controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  • Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–77

    Article  PubMed  CAS  Google Scholar 

  • Smith DC, Prentice R, Thompson DJ et al (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167

    Article  PubMed  CAS  Google Scholar 

  • Song RX, Mor G, Naftolin F et al (2001) Effect of long term oestrogen on apoptotic responses of breast cacnser cells to 17 beta-estradiol. JNCI 93:1714–1722

    Article  PubMed  CAS  Google Scholar 

  • Stefanick ML, Anderson GL, Margolis KL et al (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–1657

    Article  PubMed  CAS  Google Scholar 

  • The Women’s Health Initiative Steering Committee (2004) The effects of conjugated euine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–1712

    Article  Google Scholar 

  • Von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomised trial. J Natl Cancer Inst 97:533–535

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Anthony Howell .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Howell, A., Evans, G.D. (2010). Hormone Replacement Therapy and Breast Cancer. In: Senn, HJ., Otto, F. (eds) Clinical Cancer Prevention. Recent Results in Cancer Research, vol 188. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-10858-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-10858-7_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-10856-3

  • Online ISBN: 978-3-642-10858-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics